NCT07689240 Pembrolizumab Clear Cell Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07689240—Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why NCT07689240 is a hot trial to watch
Clear Cell Renal Cell Carcinoma is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. NCT07689240 is notable because it tests Pembrolizumab in a Phase 3 design with Disease-free survival (DFS) as a primary decision variable. The wider PatSnap topic query returned 862 trial records and 2,423 result records, so differentiation depends on evidence quality rather than activity alone.
PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07689240 |
| Official title | Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma |
| Phase / status | Phase 3 / Not yet recruiting |
| Intervention | Pembrolizumab |
| Sponsor | National Cancer Institute |
| Geography | Not reported |
| Enrollment | 400 |
| Primary endpoint | Disease-free survival (DFS) |
| Endpoint time frame | From randomization to first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first, assessed up to 10 years |
| Primary completion | 2032-01-01 |
| Study completion | 2032-01-01 |
Design and endpoint interpretation
The design should be read as an evidence architecture, not just a phase label. The primary endpoint—Disease-free survival (DFS)—determines what uncertainty this study can resolve. The reported time frame is From randomization to first documented local recurrence, distant metastasis, secondary systemic malignancy, or death due to any cause, whichever occurs first, assessed up to 10 years. Enrollment of 400 participants and geography in Not reported shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.
Benchmark readouts in the same clinical field
- Phase II Study of CC-5013 in Patients With Advanced Renal Cell Carcinoma (RCC) (Phase 2): ORR = 3 Participants ; -; -.
- Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2α (Phase 3): AE(Grade ≥3) = 55.0 % .
- A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC) (Phase 1/2): Grade 3 or greater AEs = 12 Participants ; Grade 3 or greater AEs = 7 Participants ; -; -; -.
These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.
Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: Pembrolizumab (Approved; PD-1).
Company & Deal Intelligence context: National Cancer Institute — http://www.cancer.gov.
The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: randomized data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.
What to monitor next
Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.
Bottom line
NCT07689240 is a focused lens on Clear Cell Renal Cell Carcinoma development. Its value will be determined by whether Pembrolizumab can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
